160
Participants
Start Date
May 31, 2024
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2025
Gadopiclenol
Gadopiclenol is an FDA-approved gadolinium-based contrast agent (GBCA) for neurological and abdominal contrast-enhanced MRI. Participants will receive this contrast agent at one of three different doses prior to undergoing a congenital heart cardiac MRI/MRA. This contrast agent will be compared to gadobenate dimeglumine, the standard-of-care.
Gadobenate dimeglumine
Gadobenate dimeglumine is an FDA-approved GBCA that is used in standard clinical practice at UCSD for contrast-enhanced MRI/MRA studies, including cardiac MRI/MRA. This contrast agent is the standard of care to which gadopiclenol will be compared.
University of California San Diego Health, San Diego
Bracco Imaging S.p.A.
INDUSTRY
University of California, San Diego
OTHER